Compare AGCO Corporation (AGCO) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance

AGCO Corporation

Alnylam Pharmaceuticals, Inc.

Price performance

Price movement over the last 24 hours

Key statistics

AGCO Corporation vs Alnylam Pharmaceuticals, Inc. — how do they compare? AGCO Corporation trades at $113.41 (market cap $8.24B), while Alnylam Pharmaceuticals, Inc. trades at $322.01 (market cap $42.94B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 5.2× AGCO Corporation's market cap, and AGCO Corporation pays a 1.05% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.

	AGCO	ALNY
Market Cap	$8.24B	$42.94B
Sector	Industrials	Health
52-Week High	$140.49	$491.22
52-Week Low	$100.14	$278.09
Enterprise Value	$10.41B	$41.20B
Dividend Yield	1.05%	—

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

AGCO

AGCO declares $0.30 quarterly dividend payable September 15, 2026PRNewsWire · 9 hours agoBullish View details →

ALNY

Transthyretin Amyloidosis Treatment Market to hit $35.1B by 2035, growing at 14.64% CAGR driven by new RNAi therapies and diagnostics.Sns Insider · 1 day agoBullish Transthyretin Amyloidosis Treatment Market to hit $35.10B by 2035 with 14.64% CAGR, driven by gene-silencing therapies and diagnostics.Globe News Wire · 1 day agoBullish View details →

About AGCO Corporation

Agco is a global manufacturer of agricultural equipment. The company has five principal brands: Fendt, Massey Ferguson, Challenger, Valtra, and GSI. Unlike its competitors, Agco's product line extends beyond self-propelled equipment and implements by offering grain handling systems and livestock management solutions. Its products are available through a global dealer network, which includes over 3,200 dealer and distribution locations. Additionally, Agco offers both retail and wholesale financing to customers through its joint venture with Rabobank, a European food and agriculture focused bank.

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.